Cardiac hypertrophy is a common response to circulatory or neurohumoral stressors as a mechanism to augment contractility. When the heart is under sustained stress, the hypertrophic response can evolve into decompensated heart failure, although the mechanism(s) underlying this transition remain largely unknown. The dynamics of cardiac contraction and relaxation are fundamentally related to actinmyosin interactions: Initiated by Ca2+-induced Ca2+ release, Ca2+ binds to troponin C, which releases tropomyosin from preventing actin participating in cross-bridge formation. A range of factors regulate this process and contribute to the adaptation of cardiac function Correspondence to The Editors,
Summary-A volume challenge unmasks left ventricular diastolic dysfunction and therefore has been proposed as a way to identify heart failure with preserved ejection fraction. However, the normal hemodynamic response to a volume challenge and how age and sex affect this relationship remain unknown. In the present study, we assessed ageand sex-related normative responses of pulmonary capillary wedge pressure to rapid saline infusion (100-200 mL/min) in 60 healthy subjects. Hemodynamic responses to saline infusion in 11 patients with heart failure with preserved ejection fraction were then compared with those in healthy young and older subjects. Rapid saline infusion significantly increased pulmonary capillary wedge pressure from 10±2 to 16±3 mm Hg with ≈1 L saline and to 20±3 mm Hg with ≈2 L saline in healthy subjects. More than 90% of the healthy subjects exhibited pulmonary capillary wedge pressure values previously considered to define heart failure with preserved ejection fraction (>15 mm Hg) with ≈2 L saline. In older women, a greater increase in pulmonary capillary wedge pressure relative to volume infused was observed compared with men and younger women, suggesting more dramatic loss of diastolic reserve in older women. The greatest increase in pulmonary capillary wedge pressure relative to volume infused was noted in patients with heart failure with preserved ejection fraction, consistent with the most severely impaired diastolic reserve. These data could constitute an important step for the development of diagnostic protocols for the invasive evaluation of patients with dyspnea. Future studies will assess how effectively saline loading differentiates patients with heart failure with preserved ejection fraction from patients with other cardiovascular diseases such as systemic and pulmonary arterial hypertension.
Conclusions-Filling pressures rise significantly with volume loading, even in healthy volunteers. Older women and patients with heart failure with preserved ejection fraction exhibit the largest increases in pulmonary capillary wedge pressure and mean pulmonary arterial pressure. 1
Loss of AngiomiR-126 and 130a in Angiogenic Early Outgrowth Cells From Patients With Chronic Heart Failure: Role for Impaired In Vivo Neovascularization and Cardiac Repair Capacity
Summary-Cell-based cardiac repair mechanisms such as that stimulated by angiogenic early outgrowth cells (EOCs) or CD34+ cells are currently being intensely examined as a potential therapeutic target in patients with chronic heart failure (CHF) caused by ischemic cardiomyopathy. Clinical studies have suggested that administration of angiogenic EOCs may improve cardiac function, but the effects have been more modest compared with experimental studies, particularly in patients with ischemic cardiomyopathy. These observations raised the question of what underlying molecular mechanisms limit the cardiac repair capacity of angiogenic EOCs or CD34+ cells derived from patients with CHF caused by ischemic cardiomyopathy. Recent experimental studies have indicated that the angiogenic effects of these cells are important to promote cardiac repair and to improve cardiac function. In the present study, we have observed that cardiac neovascularization and repair capacity of angiogenic EOCs derived from patients with CHF caused by ischemic cardiomyopathy were substantially impaired compared with angiogenic EOCs from healthy subjects. MicroRNAs, small noncoding RNAs, have been identified as key regulators of angiogenic processes. Here, we have shown a marked downregulation of the proangiogenic microRNA-126 in angiogenic EOCs and CD34+ cells from patients with CHF. Moreover, miR-126 mimic transfection of angiogenic EOCs from patients with CHF increased their capacity to enhance cardiac neovascularization and to improve cardiac function. These studies identify a novel mechanism limiting the cardiac repair capacity of angiogenic EOCs and CD34+ cells in patients with CHF that can be therapeutically targeted by miR-126 mimic treatment.
Conclusions-The present study reveals a loss of angiomiR-126 and -130a in angiogenic EOCs and circulating CD34+ cells from patients with CHF. Reduced miR-126 expression was identified as a novel mechanism limiting their capacity to improve cardiac neovascularization and function that can be targeted by miR-126 mimic transfection. 2 to physiological or pathological stressors, which could suggest a prominent therapeutic strategy for heart failure. Myosin is a hexamer composed of 2 heavy chains and 2 pairs of light chains (MLC1 and MLC2) located on the rod and neck regions of the heavy chain, respectively. Phosphorylation of MLC2v has been shown to potentiate the rate and force of cardiac contraction. In this study, we demonstrated that the kinase that phosphorylates MLC2 and cardiac myosin lightchain kinase play essential roles in cardiac adaptations to pressure overload. Development of heart failure under pressure overload is attenuated by greater expression of cardiac myosin light-chain kinase without apparent adverse effects on normal cardiac function in the absence of increased loading. Thus, an increase in the expression of cardiac myosin light-chain kinase or an enhancement of its function is a potentially important therapeutic target for the treatment of heart failure resulting from pressure overload (ie, hypertensive heart failure).
Conclusions-Our results suggest the novel idea that accelerated cMLCK protein turnover by the ubiquitin-proteasome system underlies the transition from compensated hypertrophy to decompensated heart failure as a result of reduced phosphorylation of MLC2v. 3
Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator
Summary-Multiple randomized clinical trials have demonstrated that ambulatory heart failure with moderate heart failure symptoms and an ejection fraction of <35% derive a survival benefit from an implanted cardiac defibrillator for primary prevention of sudden death. The implantable cardioverter-defibrillator (ICD) can be life-saving to patients at risk for sudden death attributable to ventricular arrhythmias. Recently published meta-analysis have raised the possibility that women may not benefit as much from ICDs and have less appropriate ICD shocks compared with men with heart failure. The possibility that women may not derive as much benefit from an ICD is plausible, as it is well understood that men and women differ significantly in the epidemiology, pathophysiology, and natural history of heart failure. Further, randomized studies evaluating the role of the ICD for primary prevention of sudden death are not unlike most studies in heart failure in that there is a significant underrepresentation of women in these studies. Relevant to this question, we evaluated the sex differences in mode of death in 8337 ambulatory heart failure patients, including 1685 (20%) women, who would qualify for a primary prevention ICD. Although age-adjusted total mortality was 24% lower in women compared with men, the annual mortality for women in this study was significant (9.1%). When compared with men, women were 31% less likely to die of sudden death. These findings provide a plausible reason for potential differences in ICD benefit between men and women and lend further support for the need for randomized studies aimed at defining the role of the ICD in the primary prevention of sudden death in women.
Conclusions-Women with heart failure have a lower mortality than men, and fewer of those deaths are sudden throughout a spectrum of allcause mortality risk. These data provide a plausible reason for and thus support the possibility that sex differences in ICD benefit may exist. 4
Secretory Products From Epicardial Adipose Tissue of Patients With Type 2 Diabetes Mellitus Induce Cardiomyocyte Dysfunction
Summary-Cardiac contractile dysfunction and myocardial insulin resistance frequently occur in patients with type 2 diabetes mellitus. Recent studies link adipose tissue-derived factors, termed adipokines, to the pathogenesis of these cardiac alterations. Epicardial adipose tissue a visceral thoracic fat depot surrounding the aortic arch, the large coronary arteries, the ventricles, and the apex of the human heart. Because no fascial boundaries separate the epicardial adipose tissue from the myocardium, factors released from this fat depot may directly affect the underlying tissues. In patients with type 2 diabetes mellitus, the adipose tissue is characterized by a chronic state of inflammation, which results in alterations in adipokine secretion. The present studies investigated whether alterations in the secretory profile of epicardial adipose tissue in patients with type 2 diabetes mellitus occur, and whether these alterations affect contractile function and insulin sensitivity in rat cardiomyocytes. Epicardial biopsies of patients with type 2 diabetes mellitus were characterized by clusters of CD14-positive monocytes and CD68-positive macrophages, which are both indicative of inflammation. Exposing cardiomyocytes to conditioned media prepared from epicardial adipose tissue from patients with type 2 diabetes mellitus induced reductions in contractile function and insulin resistance. These effects could be ascribed to a selective accumulation of activin A and angiopoietin-2 in the conditioned media. Collectively, these data show that inflammation of epicardial adipose tissue in patients with type 2 diabetes mellitus is associated with alterations in adipokine secretion, which may contribute to the pathogenesis of type 2 diabetes mellitus-related heart disease.
Conclusions-Collectively, our data implicate type 2 diabetes mellitus-related alterations in the secretory profile of epicardial adipose tissue in the pathogenesis of diabetes mellitus-related heart disease. 5
Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations
Summary-The standard method of analysis of deaths and hospital admissions in clinical trials that only considers first events may no longer be the most appropriate approach as cardiovascular diseases become more chronic conditions, increasingly characterized by recurrent nonfatal episodes. We examined alternative approaches, taking account of repeat heart failure hospitalizations (HFHs) in the The Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure trial (EMPHASIS-HF). During the median 25 months extended double-blind follow-up, 186 of 1364 (14%) of eplerenone-treated and 277 of 1373 (20%) of placebo-treated patients experienced at least 1 HFH, ie, a relative risk reduction of 32% (95% confidence interval, 20-43); P<0.0001, or 6 fewer HFHs per 100 patients treated. There were a total of 312 HFH (10.7 per 100 personyears) in the eplerenone group in comparison with 481 (17.0) in the placebo group, giving a rate ratio of 0.63 (95% confidence interval, 0.55-0.73); P<0.0001, or 12 fewer HFHs per 100 patients treated. Of the 481 total HFHs in the placebo group, 204 (42%) did not count in the time-to-first-event analysis. In the eplerenone and placebo groups, there were 186 (6.4 per 100 person-years) and 277 (9.7) first HFH, respectively, giving a Poisson rate ratio of 0.65 (95% confidence interval, 0.54-0.73); P<0.0001. A negative binomial regression model used to analyze repeat HFH (excluding the first), gave a rate ratio of 0.52 (95% confidence interval, 0.33-0.82); P=0.004. Analyses of repeat events may give a better assessment of the effect of treatment on the burden of chronic diseases such as heart failure.
Conclusions-Eplerenone markedly reduces the risk of heart failure hospitalizations in patients with heart failure and mild symptoms to a greater extent than is captured by only studying the time to first hospitalization. Future clinical trials in heart failure would gain from incorporating repeat hospitalizations into their primary evaluation of treatment effects. 6
Targeted Sarcoplasmic Reticulum Ca2+ ATPase 2a Gene Delivery to Restore Electric Stability in the Failing Heart
Summary-Sudden arrhythmic death is a major risk in heart failure, yet the mechanisms are incompletely understood. T-wave alternans arises from beat-to-beat alternans of cellular repolarization, is a consistent precursor to ventricular fibrillation in experimental animals, and is a marker of electric instability in patients. Previously, we reported that sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a), the pump responsible for reuptake of cytosolic calcium during diastole, plays a central role in the molecular mechanism of cardiac alternans. In the present study, SERCA2a gene transfer in the failing heart not only improved contractile function but also restored electric stability through the amelioration cardiac alternans and sarcoplasmic reticulum Ca2+ leak. This finding provides evidence that dysfunctional sarcoplasmic reticulum Ca2+ cycling links contractile and electrophysiological dysfunction in the failing heart and that therapy targeting key sarcoplasmic reticulum Ca2+ cycling proteins (ie, SERCA2a) can restore both contractile function and electric stability. Thus, therapies targeting SERCA2a warrant further evaluation in heart failure.
Conclusions-These data show that SERCA2a gene transfer in the failing heart not only improves contractile function but also directly restores electric stability through the amelioration of key arrhythmogenic substrate (ie, cardiac alternans) and triggers (ie, sarcoplasmic reticulum Ca2+ leak). 7
G13-Mediated Signaling Pathway Is Required for Pressure Overload-Induced Cardiac Remodeling and Heart Failure
Summary-Cardiac remodeling in response to pressure or volume overload plays an important role in the pathogenesis of heart failure. Various mechanisms have been suggested to translate mechanical stress into structural changes, eg, the release of humoral factors such as angiotensin II and endothelin-1, which are believed to induce cardiac hypertrophy through activation of receptors coupled to the Gq/11 family of heterotrimeric G proteins. Most Gq/11-coupled receptors, however, can also activate G proteins of the G12/13 family, but the role of G12/13 in cardiac remodeling is not understood. We show in this study that inducible, cardiomyocyte-specific inactivation of the α subunit of G13, Gα13, does not affect basal heart function but protects mice from pressure overload-induced hypertrophy and fibrosis as efficiently as inactivation of Gαq/11. Furthermore, inactivation of Gα13 prevents the development of heart failure up to 1 year after overloading. On the molecular level, we show that Gα13, but not Gαq/11, controls agonist-induced expression of hypertrophy-specific genes through activation of the small GTPase RhoA and consecutive activation of myocardin-related transcription factors. Taken together, our results show that the signaling cascade Gα13-RhoA-myocardin-related transcription factor regulates the expression of hypertrophic and fibrotic genes in cardiomyocytes. The finding that inactivation of Gα13 prevents cardiac decompensation for up to 1 year after the onset of pressure overload makes this signaling pathway a promising target for therapeutic intervention in chronic heart failure.
Conclusions-Our data show that the G12/13 family of heterotrimeric G proteins is centrally involved in pressure overload-induced cardiac remodeling and plays a central role in the transition to heart failure. 8
Multiple Reaction Monitoring to Identify Site-Specific Troponin I Phosphorylated Residues in the Failing Human Heart
Summary-Phosphorylation of cardiac troponin I, a myofilament protein, regulates myocyte function. Using mass spectrometry, we established that human cardiac troponin I is more extensively phosphorylated than previously reported, with 14 modifiable amino acid residues located throughout its entire length. Six novel phosphorylated amino acid residues were identified in functionally important regions of cardiac troponin I. Furthermore, sensitive mass spectrometry-based assays were developed to simultaneously quantify the extent of phosphorylation of each modifiable residue in control and human failing myocardium. Along with the heart failure-related dephosphorylation of known protein kinase A-targeted sites, we found increased phosphorylation of protein kinase C sites and several of the newly identified sites found in the C terminus of cardiac troponin I. In a canine model of heart failure with dyssynchrony, these C-terminal sites were hyperphosphorylated, and this change shifted back toward normal with cardiac resynchronization. These findings suggest correlation of phosphorylation of cardiac troponin I with functional status and potential utility as a tissue biomarker and therapeutic target.
Conclusions-Selective, functionally significant phosphorylation alterations occurred on individual residues of cardiac troponin I in heart failure, likely reflecting an imbalance in kinase/phosphatase activity. Such changes can be reversed by cardiac resynchronization. 9
Dipeptidyl Peptidase-4 Modulates Left Ventricular Dysfunction in Chronic Heart Failure via Angiogenesis-Dependent and -Independent Actions
Summary-Dipeptidyl peptidase-4 (DPP4) is a serine protease with a primary function of truncating various bioactive molecules such as incretin hormones, angiogenic chemokines, inflammatory cytokines, denatured collagen, and brain natriuretic peptide. To date, the pathophysiological significance of DPP4 in the processes of diabetes mellitus, malignancy, and inflammation has been well recognized and well established; however, the role of DPP4 in the pathogenesis of cardiovascular disease remained unclear until as recently as several years ago, when the first report demonstrated the protective role of DPP4 inhibition in acute myocardial infarction. The present study highlights a novel pathophysiological role for DPP4 in diastolic left ventricular dysfunction and raises the possibility of using DPP4 as a diagnostic surrogate and a therapeutic target for chronic heart failure. One of the primary interpretations drawn from the present study is that the coronary microcirculation is essential for diastolic left ventricular dysfunction development, in which DPP4 may play a pathophysiological role by regulating coronary angiogenesis. Diabetes mellitus has been postulated to exacerbate heart failure, and the comorbidity of diabetic retinopathy, ie, diabetic microvasculopathy, has been suggested to be associated with the increased incidence of heart failure in patients with diabetes mellitus. Thus, the present study proposes another therapeutic benefit of the small-molecule DPP4 inhibitors in reducing the incidence of heart failure in patients with diabetes mellitus. 
Conclusions

Carnitine Palmitoyltransferase-1b Deficiency Aggravates Pressure Overload-Induced Cardiac Hypertrophy Caused by Lipotoxicity
Summary-The present study based on a mouse model with heterozygous carnitine palmitoyltransferase-1b (CPT1b) deficiency demonstrated that CPT1b deficiency is detrimental to the heart under left ventricular pressure-overload conditions. This finding contrasts with the common view that fatty acid oxidation (FAO) depression may be beneficial for the heart in the progression of cardiac hypertrophy and heart failure. It is recognized that myocardial FAO provides the majority of cardiac energy in a normal heart. However, the more oxygen-consuming FAO becomes a burden for the heart under hypertrophy and heart failure conditions. Consequently, the heart switches to use glucose as the main fuel with better energy efficiency. Therefore, compounds of FAO inhibitors targeting various FAO steps for the treatment of cardiac hypertrophy and heart failure have been developed and tested. Some beneficial effects have been shown in small clinical trials, especially for CPT1 inhibitors. However, this therapy is also associated with adverse effects. These untoward effects limit clinical utility and highlight the need for more preclinical studies. A major hurdle for the clinical use of this class of drugs is the lack of understanding of the potential detrimental effects of FAO deficiency in the heart under pathological conditions. Therefore, the present studies based on a genetic mouse model should provide definitive insights into the potential problems with the clinical use of this class of drugs to treat cardiac hypertrophy and heart failure.
Conclusions-CPT1b deficiency can cause lipotoxicity in the heart under pathological stress, leading to exacerbation of cardiac pathology. Therefore, caution should be exercised in the clinical use of CPT1 inhibitors. 11
Myocardial Relaxation, Restoring Forces, and Early-Diastolic Load Are Independent Determinants of Left Ventricular Untwisting Rate
Summary-Measurement of the left ventricular (LV) untwisting rate (UTR) by speckle tracking echocardiography represents a means to evaluate diastolic function, and UTR has been proposed as a marker of the rate of LV relaxation. The present experimental study confirmed the relationship between peak UTR and rate of LV relaxation. In addition, restoring forces generated by systolic contraction, analogous to the elastic recoil after release of a compressed spring, was another important independent determinant of peak UTR. Furthermore, the present study indicated that early-diastolic load, measured as LV pressure at the onset of filling, is an important and independent determinant of peak UTR. Therefore, in the assessment of LV relaxation rate by measurement of peak UTR, one needs to take into account LV diastolic pressure and the magnitude of restoring forces, as well. Clinically, early-diastolic load would approximate LV end-diastolic pressure, and restoring forces may be reflected in end-systolic volume. The demonstration that restoring forces and early-diastolic load are independent determinants of peak untwisting rate, in addition to the rate of relaxation, may have an impact on how measurements of untwisting rate are interpreted in a clinical context. LV untwisting occurs during LV relaxation and early filling and is therefore a feature of diastole. However, because restoring forces are generated by systolic contraction, changes in peak UTR may also be attributed to changes in contractility. Therefore, it may not be appropriate to conclude that a change in peak UTR reflects a true change in diastolic function.
Conclusions-The present study indicates that early-diastolic load, restoring forces, and relaxation rate are independent determinants of peak UTR. However, only relaxation rate and restoring forces contributed to UTR during isovolumic relaxation. 12
Dissociation of Structural and Functional Phenotypes in Cardiac Myosin-Binding Protein C Conditional Knockout Mice
Summary-Mutations in the gene encoding cardiac myosin-binding protein-C (cMyBP-C) are common causes of familial hypertrophic cardiomyopathy (HCM) and can also lead to HCM-associated dilation. This primary disease of the myocardium affects a wide range of patient age groups, accounts for the majority of cardiac genetic diseases, and leads to significant morbidity and mortality associated with the development of heart failure, ventricular and atrial arrhythmias, myocardial infarction, and sudden cardiac death. Nevertheless, little is known regarding the mechanisms underlying the development of cMyBP-C-associated HCM, although deficiencies in cMyBP-C are thought to contribute to the pathogenesis of this disease in many cases. Herein, we investigate the onset, progression, and saturation of structural and functional phenotypes caused by the removal of cMyBP-C and assess whether loss of cMyBP-C per se is sufficient to cause the development of HCM-associated dilation.
Using adult cMyBP-C conditional knockout mice, we show that acute loss of cMyBP-C affects the duration of cardiac systole and diastole and contributes to the development of diastolic dysfunction, all of which occurs before the onset of cardiac hypertrophy. Moreover, we show that near-complete ablation of cMyBP-C is insufficient to cause HCM-associated dilation in adult mice, whereas the imposition of additional stresses such as increased afterload is sufficient to recapitulate the phenotype. These results help define the gradual changes that precede and progress with the clinical expression of cMyBP-C-associated cardiomyopathy and identify potential avenues in which to prevent, delay, or reverse the progression of this disease.
Conclusions-These results indicate that myocardial dysfunction is largely caused by the removal of cMyBP-C and occurs before the onset of cytoarchitectural remodeling in tamoxifen-treated cMyBP-C-cKO myocardium. Moreover, near ablation of cMyBP-C in adult myocardium primarily leads to the development of hypertrophic cardiomyopathy in contrast to the dilated phenotype evident in cMyBP-C−/− mice, which highlights the importance of additional factors such as loading stress in determining the expression and progression of cMyBP-C-associated cardiomyopathy. 13
Community Care in England: Reducing Socioeconomic Inequalities in Heart Failure
Summary-Although we appeared to be facing a heart failure epidemic before the millennium, recent reports suggest that the incidence and prevalence of heart failure are falling. The delivery of survival-enhancing therapies has simultaneously increased. However, the fundamental goal of health care is to improve not only effectiveness but also equity. The present study examined these trends according to socioeconomic status using nationally representative primary care data from England. Heart failure incidence and prevalence continued to decrease, paralleled by improvements in uptake of disease-modifying therapies. Although gradients were apparent, the frequency of heart failure declined more in the most deprived, and the absolute gap between the deprived and affluent was reduced. In just 8 years, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake increased from 46% to 64%, β-blocker uptake increased from 12% to 41%, and spironolactone uptake increased from 3% to 20%. Reassuringly, no socioeconomic gradients were observed for any therapy in men or women of any age. Moreover, outcomes for patients were also equitable regardless of socioeconomic status. These are important messages for policy makers and those contemplating reform of health systems: Leveling up is achievable, increasing average levels while simultaneously reducing inequalities. However, there is no room for complacency. Future strategies should aim to address the wider determinants of heart failure, to increase treatment levels further, and to eradicate remaining inequalities. Only then will the goals of universal health care truly be realized.
Conclusions-Socioeconomic gradients in the incidence and prevalence of heart failure are reducing. Treatment is generally equitable and independent of socioeconomic circumstances. Most important, no significant inequality in outcomes was apparent. Future strategies should continue to address inequalities in the underlying causes of heart failure and to increase overall treatment levels further. 14
Pathological Cardiac Hypertrophy Alters Intracellular Targeting of Phosphodiesterase Type 5 From Nitric Oxide Synthase-3 to Natriuretic Peptide Signaling
Summary-Phosphodiesterase type 5 (PDE5) hydrolyzes cGMP, and its inhibition is widely used to treat erectile dysfunction and pulmonary hypertension. Recent studies have expanded its role to the cardiomyocyte because PDE5 inhibitors also suppress remodeling and improve function in heart diseases such as hypertrophy, infarction, and dilated heart failure. These preclinical data have spawned clinical trials in heart failure. In the normal myocyte, PDE5 degrades cGMP generated by nitric oxide-stimulated soluble guanylate cyclase but has virtually no impact on natriuretic peptide (NP)-derived cGMP. Yet in heart failure, cGMP from nitric oxide signaling declines whereas NP-generated cGMP rises. This poses a paradox for the inhibitor studies because, if normal PDE5 cGMP-targeting persisted in heart failure, its impact and efficacy of inhibitors should both decline.
Here, we reveal an explanation, showing in the hypertrophied/dilated heart that PDE5 is retargeted to degrade NP-cGMP. Even in mice in which nitric oxide synthase 3 is genetically deleted to remove the normal source of PDE5-targeted cGMP, upregulated myocyte PDE5 still worsened hypertrophy and left ventricular dilation/dysfunction to pressure-overload coupled to increased NP-cGMP hydrolysis. This was associated with physical displacement of PDE5 from its normal sarcomere localization to a diffuse cytosolic distribution. Enhanced myocyte PDE5 expression also stimulated reactive oxygen species. However, this was not required for its pathological effects because reactive oxygen species was greatly reduced in mice with codeletion of nitric oxide synthase 3 despite similar adverse remodeling to pressure overload. PDE5 retargeting likely contributes to cardiac NP desensitization and suggests a combined benefit from PDE5 inhibition and NP stimulation in cardiac disease.
Conclusions-These data provide the first evidence for functional retargeting of PDE5 from one compartment to another, revealing a role for natriuretic peptide-derived cGMP hydrolysis by this esterase in diseased heart myocardium. Retargeting likely affects the pathophysiological consequence and the therapeutic impact of PDE5 modulation in heart disease. 15
Effect of QRS Duration and Morphology on Cardiac Resynchronization Therapy Outcomes in Mild Heart Failure: Results From the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) Study
Summary-Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces reverse left ventricular remodeling in selected populations with both mild and advanced heart failure. Despite these benefits of CRT, nearly one third of subjects are typically classified as nonresponders. Characteristics of the surface ECG have been shown to be important predictors of response in several previous studies. In the present analysis of the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial, the impact of baseline QRS duration and morphology and the change in QRS duration with pacing on outcomes in mild heart failure with CRT were described. Patients with left bundle-branch block experienced large reductions in left ventricular volumes, whereas patients with non-left bundle-branch block had much smaller decreases. Baseline QRS duration was also a strong predictor of remodeling, with monotonic increases as QRS duration prolonged and no obvious threshold above 120 milliseconds. Similarly, clinical outcomes improved with CRT for left bundle-branch block subjects but not for non-left bundle-branch block subjects, and clinical outcomes increased as QRS duration prolonged. The change in QRS duration with CRT pacing was not an independent predictor of any outcomes after correction for baseline variables. These data indicate that left bundle-branch block and QRS prolongation are markers of reverse remodeling and clinical benefit with CRT in mild heart failure. However, the change in QRS duration with biventricular pacing is not a useful predictor of response independently of the baseline ECG characteristics. Finally, despite the relationship between QRS duration and outcomes, these results do not support the use of any arbitrary QRS duration cutoff >120 to 130 milliseconds for selecting CRT candidates.
Conclusions-REVERSE demonstrated that left bundle-branch block and QRS prolongation are markers of reverse remodeling and clinical benefit with CRT in mild heart failure. 16
Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction
Summary-Large trials testing modern heart failure pharmacotherapy in heart failure with preserved ejection fraction (HFPEF) had a neutral outcome, probably because of failure to address features of myocardial dysfunction specific for heart failure with preserved ejection fraction such as high-diastolic left ventricular stiffness. The latter results not only from myocardial fibrosis, but also from high cardiomyocyte stiffness, which is linked to hypophosphorylation of the cytoskeletal protein titin and corrected by in vitro administration of protein kinase G (PKG). In vivo administration of sildenafil, which raises myocardial PKG activity by inhibiting breakdown of cyclic guanosine monophosphate, similarly improves diastolic left ventricular stiffness in a HFPEF dog model and HFPEF patients with pulmonary hypertension. Because of these findings and the ongoing RELAX trial testing sildenafil in HFPEF, the present study compared PKG activity, its downstream effects, and its upstream controls in e850 Circulation June 18, 2013 left ventricular endomyocardial biopsies of patients with HFPEF, HF with reduced ejection fraction, and aortic stenosis. Patients were free of coronary artery disease, but more HFPEF patients were obese or had diabetes mellitus. The lowest myocardial PKG activity was observed in HFPEF and associated with the highest cardiomyocyte stiffness, the lowest myocardial cyclic guanosine monophosphate concentration, and the highest myocardial nitrosative/oxidative stress. The high prevalence among HFPEF patients of metabolic disorders probably accounted for their high myocardial nitrosative/oxidative stress, which led to high cardiomyocyte stiffness through a cascade of derangements consisting of low cyclic guanosine monophosphate concentration, low PKG activity, and reduced phosphorylation of titin by PKG. Metabolic derangements therefore underlie diastolic left ventricular dysfunction in HFPEF and should be targeted in future HFPEF treatment strategies.
Conclusions-Low myocardial PKG activity in HFPEF was associated with raised cardiomyocyte Fpassive and was related to increased myocardial nitrosative/oxidative stress. The latter was probably induced by the high prevalence in HFPEF of metabolic comorbidities. Correction of myocardial PKG activity could be a target for specific HFPEF treatment. 17
MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-β1 Pathway
Summary-Myocardial infarction caused by coronary artery occlusion is one of the leading causes of sudden death in the world. Interstitial fibrosis, occurring in both infarcted and noninfarcted myocardium, represents a characteristic pathological alteration of postinfarct remodeling and is regarded as a major determinant of the progressive deterioration of ventricular function and reduced ventricular compliance after myocardial infarction. Fibrosis is characterized by excessive deposition of extracellular matrix proteins. Cardiac fibroblasts, accounting for 60% to 70% of the cells in the human heart, are the main source of extracellular matrix protein production. During myocardial infarction, cardiac fibroblasts are activated and produce excessive amount of extracellular matrix proteins, leading to interstitial fibrosis. Tremendous efforts have been devoted to this pathological process to elucidate the molecular mechanisms and to develop novel antifibrotic strategies. MicroRNAs (miRs), endogenous small noncoding RNAs that regulate the expression of genes, have recently been proven to be a novel class of regulators of cardiovascular diseases, including those associated with cardiac fibrosis. In this study, we discovered that downregulation of an miR called miR-101 contributes significantly to cardiac fibrosis in myocardial infarction hearts; forced expression of miR-101 suppresses cardiac fibrosis and improves the impaired cardiac function in postinfarct rats. Our findings reveal the role of miRNA in controlling cardiac fibrosis in myocardial infarction hearts and indicate that miR-101 is a viable therapeutic strategy for cardiac disease associated with fibrosis. It is speculated that administration of miR-101 mimetics should produce antifibrotic actions, thereby retarding structural remodeling and minimizing functional deterioration of the heart under a variety of pathological settings.
Conclusions-Overexpression of miR-101a can mitigate interstitial fibrosis and the deterioration of cardiac performance in postinfarct rats, indicating the therapeutic potential of miR-101a for cardiac disease associated with fibrosis. 18
High Levels of Circulating Epinephrine Trigger Apical Cardiodepression in a β2-Adrenergic Receptor/Gi-Dependent Manner: A New Model of Takotsubo Cardiomyopathy
Summary-Takotsubo cardiomyopathy is an increasingly recognized clinical syndrome characterized by severe acute (but reversible) apical ventricular dysfunction, ST elevation, and unobstructed coronary arteries. Physical or emotional stress is a frequent precipitant, as well as iatrogenic catecholamine exposure. We generated a model of Takotsubo cardiomyopathy using a single high bolus dose of epinephrine in anesthetized rats, which reproduced the reversible apical hypocontractility. We explored the subcellular mechanisms and identified that high-dose epinephrine activated a switch of β2-adrenergic receptor (β2AR) coupling from the positively inotropic Gs-cAMP to a negatively inotropic Gi signaling pathway. Norepinephrine, which does not activate this Gs/Gi switch, did not precipitate apical dysfunction. Proportionately higher β2AR numbers at the apex produced the apical-basal gradient in contractility. Prevention of the switch increased sudden death in this model, which is consistent with the protective antiarrhythmic and antiapoptotic nature of Gi signaling. We screened various β-blockers (given after apical dysfunction was established) using the model and noted that propranolol, which also switches β2AR to the Gi pathway, exacerbated contractile dysfunction without increasing mortality. Carvedilol had similar but less pronounced effects, and bisoprolol did not affect the response. Avoiding the βAR-cAMP axis with the calcium myofilament sensitizer levosimendan, we were able to completely rescue the acute Takotsubo syndrome, with 100% survival. This model suggests that an epinephrine-induced β2AR Gs/Gi switch is responsible for the acute apical dysfunction in Takotsubo cardiomyopathy but that it may also confer an element of protection against damage by high catecholamines.
Conclusions-We suggest that biased agonism of epinephrine for β2AR-Gs at low concentrations and for Gi at high concentrations underpins the acute apical cardiodepression observed in Takotsubo cardiomyopathy, with an apical-basal gradient in β2ARs explaining the differential regional responses. We suggest this epinephrine-specific β2AR-Gi signaling may have evolved as a cardioprotective strategy to limit catecholamine-induced myocardial toxicity during acute stress. 19
Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac Parameters: A Systematic Review and Meta-Analysis
Summary-Although adult bone marrow cell (BMC) therapy for cardiac repair appears promising, divergent data from smaller clinical trials have generated lingering controversy over the nature and extent of benefits. We performed a systematic review and meta-analysis of pooled data from 50 trials to assess the impact of BMC therapy on clinically important end points. Our results show that BMC therapy modestly improves left ventricular function and remodeling in patients with ischemic heart disease and that these benefits persist during long-term follow-up. These data also suggest that BMC therapy is associated with reduced all-cause and cardiac mortality and reduced incidence of recurrent myocardial infarction and stent thrombosis without any significant increase in adverse events. BMC therapy seems effective for both acute myocardial infarction and chronic ischemic cardiomyopathy, largely independently of the location of myocardial infarction. Patients with lower left ventricular ejection fraction at baseline appear to benefit more. To be effective, injection of at least 40 million BMCs seems necessary, and the remodeling benefits seem more pronounced with earlier BMC injection. Although BM mononuclear cells are generally more effective compared with subpopulations, cell processing techniques deserve particular attention because they influence the outcomes significantly. Finally, the magnitude of changes in various outcome parameters depends on the imaging modality, although the findings remain directionally concordant. Thus, larger clinical trials using stringent methodology and a broader array of outcomes are warranted to definitively determine the true utility of this novel therapeutic strategy for cardiac repair.
Conclusions-Transplantation of adult BMCs improves LV function, infarct size, and remodeling in patients with ischemic heart disease compared with standard therapy, and these benefits persist during long-term follow-up. BMC transplantation also reduces the incidence of death, recurrent myocardial infarction, and stent thrombosis in patients with ischemic heart disease. 20
Interleukin-10 Treatment Attenuates Pressure Overload-Induced Hypertrophic Remodeling and Improves Heart Function via Signal Transducers and Activators of Transcription 3-Dependent Inhibition of Nuclear Factor-κB
Summary-Chronic stress-induced hypertrophic growth of the myocardium leads to an increased risk of cardiovascular events, heart failure, and death. Experimental evidence suggests a potential role of inflammation in the progression of heart failure; however, the mechanisms of this process are not fully understood. The present study elucidates the novel therapeutic efficacy of the anti-inflammatory cytokine interleukin-10 (IL-10) in both the prevention and attenuation of pathological hypertrophy and heart failure in 2 models of pressure overload. Additionally, our study provides the mechanism through which IL-10 imparts its therapeutic benefits for cardioprotection. The significance of the protective effect of IL-10 is further supported by an exaggerated adverse remodeling after pressure overload in IL-10 knockout mice. Importantly, we show that pretreatment of mice with exogenous recombinant IL-10 before either isoproterenol-or transverse aortic constriction-induced hypertrophic stimulus prevents ventricular remodeling, excessive fibrosis, and cardiomyocyte death and preserves left ventricular functions. Moreover, IL-10 treatment, once hypertrophy has been established, also attenuates adverse remodeling and fibrosis in animals with pressure overload. These findings that IL-10 therapy prevents cardiac remodeling and preserves cardiac function in the face of pressure overload stress have significant bearing not only on our understanding of the mechanisms involved in IL-10 action but also on the potential future clinical and therapeutic use of IL-10 and/or its downstream signaling components for the treatment of heart failure. Thus, IL-10 treatment may be a novel therapeutic approach to prevent and cure the hypertrophic cardiac remodeling in patients.
Conclusions-Taken together, our results suggest IL-10 treatment as a potential therapeutic approach to limit the progression of pressure overload-induced adverse cardiac remodeling. 21
Proximal Cerebral Arteries Develop Myogenic Responsiveness in Heart Failure via Tumor Necrosis Factor-α-Dependent Activation of Sphingosine-1-Phosphate Signaling
Summary-This study presents a novel concept, in which the cause of reduced cerebral blood flow in heart failure lies in the tumor necrosis factor-α-and sphingosine-1-phosphate-dependent recruitment of proximal cerebral arteries into the myogenic mechanism. Our investigation further identifies this pathophysiology as a therapeutic target.
We illustrate that myogenic recruitment and consequent reductions in cerebral blood flow are reversed by tumor necrosis factor-α sequestration with etanercept, with additional benefits in cardiac function and peripheral resistance. These results challenge the notion that etanercept possesses limited usefulness for the treatment of heart failure and encourages a reevaluation using vascular and hemodynamic end points.
Conclusions-Cerebral artery vasoconstriction and decreased cerebral blood flow occur early in an animal model of heart failure; these perturbations are reversed by interrupting TNFα/S1P signaling. This signaling pathway may represent a potential therapeutic target to improve cognitive function in heart failure. 22
Remote Monitoring Reduces Healthcare Use and Improves Quality of Care in Heart Failure Patients With Implantable Defibrillators: The Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) Study
Summary-Heart failure patients with implantable defibrillators often visit the hospital for unscheduled examinations, placing a great burden on healthcare providers. Device manufacturers offer a technology for remote defibrillator monitoring with the purpose of allowing physicians to remotely access patients' data and reducing unnecessary routine and interim visits. The Evolution of Management Strategies of Heart Failure Patients With Implantable Defibrillators (EVOLVO) study was a multicenter randomized trial designed to assess whether remote management can reduce emergency healthcare use in heart failure patients implanted with defibrillators endowed with specific diagnostic features compared with standard management consisting of scheduled in-office visits and patient response to audible alerts. Over 16 months, the rate of emergency department or urgent in-office visits for heart failure, arrhythmias, or device-related events decreased by 35% and total healthcare visits were 21% less frequent with remote monitoring. Moreover, with remote monitoring system, the time from an alert condition to review of the data were reduced from 24.8 to 1.4 days, and the change in patients' quality of life was more favorable. These findings may have important implications. Indeed, our study confirmed that remote management of heart failure patients implanted with defibrillators allows timely notification of potentially critical situations. Moreover, it has the effect of shifting healthcare visits from the emergency department to the clinic and increasing the appropriateness of in-office visits, thereby reducing costs and the burden on the healthcare system. Thus, compared with the standard follow-up through in-office visits and audible alerts, remote monitoring results in increased efficiency for healthcare providers and improved quality of care for patients.
Conclusions-Remote monitoring reduces emergency department/ urgent in-office visits and, in general, total healthcare use in patients with ICD or defibrillators for resynchronization therapy. Compared with standard follow-up through in-office visits and audible ICD alerts, remote monitoring results in increased efficiency for healthcare providers and improved quality of care for patients. 23
β-Adrenergic Receptor Stimulation Transactivates Protease-Activated Receptor 1 via Matrix Metalloproteinase 13 in Cardiac Cells
Summary-Chronic heart failure of both ischemic and nonischemic etiology is accompanied by chronically elevated circulating plasma e852 Circulation June 18, 2013
catecholamines. Chronic overstimulation of cardiac β-adrenergic receptors is known to be a key contributor to the establishment and maintenance of pathological cardiac remodeling. However, the mechanism by which β-adrenergic receptor overactivation contributes to heart failure remains poorly understood. Herein, we have discovered that cardiac protease-activated receptor 1 (PAR1) (also known as the thrombin receptor) can be transactivated by β-adrenergic receptor overstimulation via the matrix metalloproteinase 13 (MMP-13, also known as collagenase 3). We propose that this mechanism plays a significant role in the establishment of cardiac dysfunction induced by chronic adrenergic overstimulation. This is of particular clinical interest because PAR1 antagonists may therefore not only prevent PAR1 activation by thrombin (in case of an ischemic event) but could in addition antagonize aspects of adrenergic-dependent pathological cardiac remodeling. Our work further suggests that MMP-13-mediated activation of PAR1 can also participate in the establishment of cardiac dysfunction. Therefore, we propose that the MMP-13/PAR1 axis represents an important novel target to treat heart failure. Drugs interfering with this axis are already available. Inhibitors of MMP-13 are currently under evaluation in animal models, primarily as a cure for rheumatoid arthritis and osteoarthritis, in which MMP-13 has been shown to play a pathological role. Moreover, antagonists of PAR1 are now undergoing clinical trials as novel antiplatelet agents. In conclusion, we suggest that MMP-13 inhibitors and PAR1 antagonists may hold therapeutic potential for the treatment of heart failure.
Conclusions-In this study, we demonstrate that β-AR stimulation leads to MMP-13 transactivation of PAR1 in both cardiac fibroblasts and cardiomyocytes and that this likely contributes to pathological activation of Gαq and ErbB receptor-dependent pathways in the heart. We propose that this mechanism may underlie the development of β-AR overstimulation-dependent cardiac dysfunction. 24
Multisite Randomized Trial of a Single-Session Versus Multisession Literacy-Sensitive Self-Care Intervention for Patients With Heart Failure
Summary-This manuscript describes the comparative effectiveness of 2 types of a heart failure self-care training program: single-session training versus multisession training. In a diverse population across 4 clinical sites, there was no difference in rate of hospitalization or death between the interventions. However, patient literacy was an important factor in the effect of the intervention. Patients with low literacy appeared to benefit from the multisession intervention compared with the single-session intervention, but patients with higher literacy did not benefit. Although self-care training for heart failure is an important component of guideline-based care for all patients, it may be important to focus our most intensive resources via ongoing training for patients with low literacy skills.
Conclusions-Overall, an intensive multisession intervention did not change clinical outcomes compared with a single-session intervention. People with low literacy appear to benefit more from multisession interventions than people with higher literacy. 25
Ventricular Assist Device Implantation Corrects Myocardial Lipotoxicity, Reverses Insulin Resistance, and Normalizes Cardiac Metabolism in Patients With Advanced Heart Failure
Summary-The failing human heart develops metabolic derangements characterized by a shift from fatty acids to glucose use for ATP generation. These metabolic changes are accompanied by transcriptional changes typically seen during embryogenesis. The aim of our study was to investigate myocardial levels of toxic lipid intermediates in samples from patients with advanced heart failure compared with control subjects. Furthermore, we analyzed whether mechanical unloading of the failing myocardium corrects impaired cardiac metabolism. For this purpose, we analyzed myocardium and serum of patients with advanced heart failure obtained during left ventricular assist device implantation and at explantation and from control subjects. Systemic insulin resistance in heart failure was accompanied by decreased myocardial triglyceride and overall fatty acid content but increased toxic lipid intermediates, diacylglycerol, and ceramide. Several downstream signaling molecules known to regulate insulin signaling (Akt, Foxo, and protein kinase C) were also found to be dysregulated in the failing myocardium, favoring an insulin-resistant state compared with control subjects. Left ventricular assist device implantation improved insulin resistance and decreased myocardial levels of the toxic lipid intermediates diacylglycerol and ceramide, whereas triglyceride and free fatty acid content remained unchanged. Therefore, abnormal myocardial metabolism, insulin resistance, and lipotoxicity develop in human heart failure. Mechanical unloading through left ventricular assist device implantation corrects systemic and local metabolic derangements in advanced heart failure. This study characterizes metabolic changes in human heart failure with the development of cardiac lipotoxicity. Furthermore, these findings suggest potential therapeutic implications of mechanical unloading of the failing myocardium for the correction of metabolic derangements in advanced human heart failure.
Conclusions-Mechanical unloading after left ventricular assist device implantation corrects systemic and local metabolic derangements in advanced heart failure, leading to reduced myocardial levels of toxic lipid intermediates and improved cardiac insulin signaling. 26
Exercise Training Attenuates MuRF-1 Expression in the Skeletal Muscle of Patients With Chronic Heart Failure Independent of Age: The Randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging Catabolism Study
Summary-Exercise intolerance in chronic heart failure (CHF) is influenced not only by the degree of left ventricular systolic dysfunction but also by peripheral skeletal muscle abnormalities, which commonly develop in advanced CHF and may progress to cardiac cachexia. Despite the clinical importance of muscle wasting in CHF, the molecular mechanisms are still largely unknown, and no specific anticatabolic treatment is currently available. In the Leipzig Exercise Intervention in Chronic Heart Failure and Aging (LEICA) study, skeletal muscle biopsies were obtained from the quadricep muscles in younger and older CHF patients and in age-matched healthy subjects to analyze whether an important signaling system for intracellular protein degradation called the ubiquitin-proteasome system was activated in heart failure and whether activation was higher with older age. We found that one of the key enzymes that marks structural proteins for protein degradation (MuRF-1) was significantly elevated in muscle biopsies from CHF patients in both age groups. Four weeks of aerobic exercise training reduced the MuRF-1 expression back to normal values. Importantly, the relative improvement did not differ between younger and older CHF patients. Understanding the specific changes causing the catabolic-anabolic imbalance in CHF is an essential first step in the development of pharmaceutical intervention strategies aimed at blocking muscle catabolism in CHF.
Conclusions-MuRF-1, a component of the ubiquitin-proteasome system involved in muscle proteolysis, is increased in the skeletal muscle of patients with heart failure. Exercise training results in reduced MuRF-1 levels, suggesting that it blocks ubiquitinproteasome system activation and does so in both younger and older CHF patients. 27
Reduced Endoglin Activity Limits Cardiac Fibrosis and Improves Survival in Heart Failure
Summary-Heart failure is a major cause of global mortality. Transforming growth factor-β1 (TGFβ1) is a cytokine that promotes cardiac fibrosis in heart failure. Endoglin is a coreceptor that regulates TGFβ1 signaling via downstream effector proteins known as Smads (canonical pathway) or mitogen-activated protein kinases (noncanonical pathway). The extracellular domain of endoglin can be cleaved into the circulation as soluble endoglin (sEng), which may serve as a natural antagonist to TGFβ1 activity. We now report that endoglin expression is increased in failing human left ventricular tissue and in a murine model of thoracic aortic constriction-induced heart failure. Using the endoglin haploinsufficient mouse model, we observed improved survival, limited cardiac fibrosis, and enhanced myocardial capillarity after thoracic aortic constriction. To study the role of endoglin in vitro, loss-of-function studies demonstrated the dependence of TGFβ1 activity on endoglin expression in human cardiac fibroblasts. Paradoxically, adenovirus-mediated overexpression of full-length endoglin also blocked TGFβ1-induced collagen synthesis. Further study showed that levels of sEng were elevated in the conditioned media after treatment with the adenovirus, thereby implicating sEng as a negative regulator of TGFβ1 activity. This observation was confirmed by adenovirus-mediated overexpression of human sEng or treatment with recombinant human sEng in vitro.
To begin exploring the utility of sEng as an antifibrotic approach in vivo, treatment with adenovirus-mediated overexpression of human sEng attenuated cardiac fibrosis in wild-type mice after thoracic aortic constriction. Together, these data identify endoglin as an important component of cardiac remodeling and a potentially novel target of therapy in heart failure.
Conclusions-Our results identify endoglin as a critical component of TGFβ1 signaling in the cardiac fibroblast and show that targeting endoglin attenuates cardiac fibrosis, thereby providing a potentially novel therapeutic approach for individuals with heart failure. 28
Tumor Necrosis Factor-α-Mediated Downregulation of the Cystic Fibrosis Transmembrane Conductance Regulator Drives Pathological Sphingosine-1-Phosphate Signaling in a Mouse Model of Heart Failure
Summary-This study brings forth the novel concept that changes in vascular cystic fibrosis transmembrane conductance regulator expression underlie the enhancement of vascular tone in heart failure. Our investigation additionally shows that this pathophysiological response is widespread, suggesting that it is a global response that may drive multiorgan dysfunction in heart failure. At the mechanistic level, the cystic fibrosis transmembrane conductance regulator functions as a key regulator of sphingosine-1-phosphate degradation, the modulation of which critically alters myogenic and vascular tone. We conclude that the cystic fibrosis transmembrane conductance regulator represents an unexplored therapeutic target for the improvement of vascular function in heart failure.
Conclusions-We identify the cystic fibrosis transmembrane conductance regulator as a critical regulatory site for S1P signaling; its tumor necrosis factor-α-dependent downregulation in heart failure underlies an enhancement in microvascular tone. This molecular mechanism potentially represents a novel and highly strategic therapeutic target for cardiovascular conditions involving inflammation. 29
Cell Therapy in Chagas Cardiomyopathy (Chagas Arm of the Multicenter Randomized Trial of Cell Therapy in Cardiopathies Study): A Multicenter Randomized Trial
Summary-Heart failure is a common cause of death in patients with chronic chagasic cardiomyopathy. Current therapies are limited and, with the exception of heart transplantation, only delay disease progression. Cell therapy using bone marrow-derived cells has been a promising (albeit inconsistent) approach to the treatment of cardiovascular diseases. Experimental evidence in animal models and feasibility studies in patients with chronic chagasic cardiomyopathy have suggested that bone marrow mononuclear cell transplantation may improve cardiac function. This study reports the results of a multicenter, doubleblind, randomized, placebo-controlled trial evaluating the efficacy of bone marrow mononuclear cells on left ventricular ejection fraction in 183 patients with chronic chagasic cardiomyopathy. Although both the placebo and cell-therapy groups showed a significant increase in left ventricular ejection fraction at 6 and 12 months of follow-up, this study failed to document a significant difference in change in left ventricular ejection fraction between the 2 groups. Intracoronary injection of bone marrow mononuclear cells was not associated with adverse clinical events. We conclude that with the methods used, no additional benefit of intracoronary mononuclear cell injection was found in patients with chronic chagasic cardiomyopathy and a left ventricular ejection fraction <35%. Nonetheless, cell-based therapies may still hold promise for chronic chagasic cardiomyopathy patients. Larger clinical trials focusing on hard clinical end points, new cell types, methods of delivery, dosage schemes, and disease stages are warranted to further test the efficacy of this novel therapeutic approach.
Conclusions-Intracoronary injection of autologous bone marrowderived mononuclear cells does not improve left ventricular function or quality of life in patients with chronic chagasic cardiomyopathy. 30
Cardiac G-Protein-Coupled Receptor Kinase 2 Ablation Induces a Novel Ca2+ Handling Phenotype Resistant to Adverse Alterations and Remodeling After Myocardial Infarction
Summary-G-protein-coupled receptor kinase 2 (GRK2) is a molecular culprit in the development and progression of heart failure (HF). We now provide the molecular basis for potential benefits of therapeutic strategies aiming at GRK2 inhibition. With our current study we demonstrate that loss of GRK2 in cardiac myocytes enhances excitation-contraction coupling in unstressed hearts and in failing myocytes. We show that this enhancement of excitationcontraction coupling occurs through differential regulation of sarcolemmal versus sarcoplasmic reticulum Ca2+ handling, with the net result being improved Ca2+ transients without sarcoplasmic reticulum Ca2+ overload leading to reversal of the HF phenotype. Further, we demonstrate that the beneficial effects seen with GRK2 inhibition in HF were associated with marked amelioration of cardiac myocyte contractility and significant improvements in intracellular Ca2+ June 18, 2013
cycling effected by modulation of the cardiac L-type Ca2+ channels. A clearly novel finding is the compartmentalization of intracellular signaling by GRK2 and thereby differential regulation of Ca2+ signaling. Overall, our current results explain the beneficial effects of GRK2 knockout in cardiac myocytes with intracellular changes in Ca2+ cycling being orchestrated to improve overall cardiac-myocyte contractility. Furthermore, our study demonstrates that this interplay between GRK2 and the L-type Ca2+ channels might represent an attractive target to correct deranged Ca2+ cycling in the failing heart. Future gene therapies or pharmacological strategies will thus potentially directly target this interplay and might thus contribute to further improvements in clinical HF treatment.
Conclusions-These data argue for novel differential regulation of L-type Ca2+ channel currents and SR load by GRK2. G-proteincoupled receptor kinase 2 ablation represents a novel beneficial Ca2+ handling phenotype resisting adverse remodeling after MI. 31
The Polyphenols Resveratrol and S17834 Prevent the Structural and Functional Sequelae of Diet-Induced Metabolic Heart Disease in Mice
Summary-The prevalence of diet-induced obesity and the metabolic syndrome is increasing at an alarming rate and is a major contributor to cardiovascular morbidity and mortality, including heart failure with a preserved ejection fraction. Polyphenols such as resveratrol and the synthetic flavonoid derivative S17834 exert beneficial systemic and cardiovascular effects in a variety of settings, including diabetes mellitus and chronic hemodynamic overload. However, the ability of the polyphenols to ameliorate metabolic heart disease associated with diet-induced metabolic syndrome is not known. We fed mice an "American" diet high in fat and sugar with or without concomitant treatment with S17834 or resveratrol for up to 8 months.
High-fat/high-sugar diet-fed mice developed left ventricular hypertrophy and diastolic dysfunction. Treatment with the polyphenols prevented the cardiac structural and functional consequences of high-fat/ high-sugar feeding. We conclude that the high-fat/high-sugar diet-fed mouse provides a valuable model of diet-induced myocardial hypertrophy and diastolic dysfunction that should prove useful in elucidating the pathobiology and treatment of metabolic heart disease. The polyphenols exerted multiple effects that may have contributed to amelioration of metabolic heart disease, including decreases in myocardial oxidative stress and oxidant-mediated protein modifications, improved insulin sensitivity, and an increase in plasma adiponectin. These findings suggest that the polyphenols could be of value in the treatment of metabolic heart disease in humans.
Conclusions-Resveratrol and S17834 administered concurrently with a HFHS diet prevent the development of left ventricular hypertrophy, interstitial fibrosis, and diastolic dysfunction. Multiple mechanisms may contribute to the beneficial effects of the polyphenols, including a reduction in myocardial oxidative stress and related protein modifications, amelioration of insulin resistance, and increased plasma adiponectin. The polyphenols resveratrol and S17834 may be of value in the prevention of diet-induced metabolic heart disease. 32
The Heart in Friedreich Ataxia: Definition of Cardiomyopathy, Disease Severity, and Correlation With Neurological Symptoms
Summary-Friedreich ataxia (FA) is an autosomal recessive neurodegenerative disease caused by a defect in the gene encoding for the mitochondrial protein frataxin. Myocardial involvement in FA is well documented, with concentric left ventricular hypertrophy as the dominating cardiac finding. Average life expectancy in FA patients with cardiac involvement is considerably reduced to 29 to 38 years. Echocardiography is the routine imaging technique of choice for the evaluation and follow-up of cardiac involvement in patients diagnosed with FA. The present cross-sectional study in >200 patients describes in detail the clinical presentation with the use of standard echocardiography, color Doppler myocardial imaging, cardiac MRI, ECG, and exercise testing. According to findings from this study, clinical grouping of the cardiomyopathy associated with FA should be based on echocardiographic wall thickness of the septum and ejection fraction. Furthermore, exercise capacity of FA patients is not affected by the severity of the cardiomyopathy but rather by neurological involvement. The provided definition of cardiomyopathy, classification of disease severity, and description of the interaction with neurology should add to the standard of care for this rare disease.
Conclusions-We provide and describe a readily applicable clinical grouping of the cardiomyopathy associated with FA based on echocardiographic end-diastolic interventricular septal wall thickness and ejection fraction data. Because no distinct interrelations between FA-CM and neurological status could be determined, regular followup of potential cardiac involvement in FA patients is essential in clinical practice. 33
Renal Sympathetic Denervation Suppresses De Novo Podocyte Injury and Albuminuria in Rats With Aortic Regurgitation
Summary-There is increasing awareness of the cardiorenal syndrome in patients with myocardial disease. The presence of chronic kidney disease is a significant and independent risk factor for poor prognosis in patients with chronic heart failure. In the present study, we demonstrated that inappropriate activation of the sympathetic nervous system and intrarenal renin-angiotensin system mediates de novo albuminuria in rats subjected to aortic regurgitation. Renal denervation reduced intrarenal angiotensinogen and angiotensin II levels and decreased podocyte injury and albuminuria in aortic regurgitation rats. Furthermore, treatment with olmesartan, to block renin-angiotensin system activity, enhanced the suppressive effects of renal denervation on albuminuria. Renal denervation also significantly reduced the induction of genes involved in fetal gene programming such as β-myosin heavy chain and brain natriuretic peptide and reduced markers of cardiac fibrosis such as collagen I and III mRNA levels and collagen content in the left ventricle. Our results imply that patients with cardiac dysfunction may be at increased risk for de novo renal dysfunction or worsening of preexisting asymptomatic renal dysfunction through sympathetic nerve hyperactivity. Recent clinical trials have demonstrated that catheter-based renal denervation can safely reduce blood pressure in treatment-resistant hypertensive patients without significant adverse events. The molecular mechanism underlying this pathophysiological condition may provide a new therapeutic target for patients with cardiovascular disease to prevent further renal injury while providing stronger protection of both organs.
Conclusions-In this chronic cardiac volume-overload animal model, activation of the sympathetic nervous system augments kidney reninangiotensin system and oxidative stress, which act as crucial cardiorenal mediators. Renal denervation and olmesartan prevent the onset and progression of renal injury, providing new insight into the treatment of cardiorenal syndrome. 34
Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity
Summary-Mitral regurgitation (MR) induces chronic left ventricular volume overload and leads to left ventricular contractile dysfunction, heart failure, and, finally, death. Although surgical correction of MR, the only definitive cure, carries reasonably low mortality and morbidity risks, medical therapeutics have a role in many clinical situations such as in a patient population with greater surgical risk. However, there is currently no recommended pharmacological therapy for chronic MR. Despite previous efforts, medical therapies for chronic MR have produced disappointing and conflicting results. Since the early 2000s, sildenafil, part of a class of selective inhibitors of phosphodiesterase type 5, has been under intense study in various areas. Multiple lines of preclinical and clinical evidence support a therapeutic role for phosphodiesterase type 5 inhibition with sildenafil in the management of heart failure. Accordingly, we hypothesized that sildenafil may have a beneficial effect in chronic MR. The major findings of the present study are that sildenafil prevented left ventricular remodeling and exercise intolerance caused by chronic experimental MR. To our knowledge, this is the first study that shows that sildenafil is efficacious in the presence of MR. Additionally, we proposed potential mechanisms related to the effect of sildenafil: inhibition of inflammation and apoptosis. With consideration of the beneficial effects of sildenafil in MR rats, we can expect a therapeutic potential for sildenafil in patients with MR. Future clinical studies are needed.
Conclusions-Sildenafil significantly attenuates LV remodeling and prevents exercise intolerance in a rat model of chronic MR. This benefit may be associated with the antiapoptotic, anti-inflammatory effects of sildenafil. 35
Regulatory Role of Dendritic Cells in Postinfarction Healing and Left Ventricular Remodeling
Summary-Left ventricular (LV) remodeling after myocardial infarction is a process of complex architectural myocardial alteration and is associated with a poor clinical outcome. Congestive heart failure due to postinfarction LV remodeling remains an open question for clinicians throughout the world, in spite of recent aggressive revascularization and pharmacological therapy in clinical practice. Inflammation and immune responses are integral components of the host reaction to myocardial injury and play a pivotal role in infarct healing and subsequent LV dysfunction. The dendritic cell (DC) is like a maestro conducting various types of inflammatory cells in innate and adoptive immunity. We found that temporal and spatial characteristics of heartinfiltrating DCs and conditional depletion of DCs resulted in adverse infarct expansion and LV dysfunction. This was accompanied by a sustained enhanced inflammatory response and extracellular matrix degradation and suppressed myocardial neoangiogenesis. This impaired tissue repair was associated with augmented infiltration of inflammatory Ly6Chigh monocytes and F4/80+ CD206− M1 macrophages and, conversely, reduced recruitment of anti-inflammatory Ly6Clow monocytes and F4/80+ CD206+ M2 macrophages in the infarcted heart.
These data indicate that DC is a potent immunoprotective regulator that acts via control of monocyte/macrophage homeostasis during the postinfarction healing process. Modulation of DCs could be a novel therapeutic target in LV remodeling after myocardial infarction.
Conclusions-These results suggest that the DC is a potent immunoprotective regulator during the postinfarction healing process via its control of monocyte/macrophage homeostasis. 36
Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction: Insights From the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study
Summary-In patients with left ventricular systolic dysfunction with or at high risk of heart failure in the postinfarction setting, adding eplerenone to standard care improves outcome even if these patients exhibit moderate reductions in estimated glomerular filtration rate, despite causing a slightly greater early reduction in estimated glomerular filtration rate compared with placebo. An early decline in estimated glomerular filtration rate by >20% was associated with worse cardiovascular outcomes independently of baseline estimated glomerular filtration rate and of the use of eplerenone, which nevertheless retained its prognostic benefits even under such circumstances. Eplerenone did not alter the usual long-term decline in renal function that occurs in this elderly population.
Conclusions-In patients with heart failure after acute myocardial infarction and receiving standard medical care, an early decline in estimated glomerular filtration rate is not uncommon and is associated with poor long-term outcome. Eplerenone induced a moderately more frequent early decline in estimated glomerular filtration rate, which did not affect its clinical benefit on cardiovascular outcomes. 37
Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading
Summary-Right ventricular dysfunction is a major independent predictor of death in patients with elevated afterload from pulmonary hypertension. We analyzed data from >1000 right heart catheterizations to show that, unlike the systemic circulation, pulmonary vascular resistance (RPA) and compliance (CPA) display a highly predictable, inverse correlation and that this relationship is not significantly altered by pulmonary hypertension or severe pulmonary fibrosis and is altered only minimally by aging. This means that, unlike the proximal aorta in the systemic circulation, the main pulmonary artery contributes relatively little to overall CPA and is little affected by age. The consistent RPA-CPA relation allows the prediction of RPA decline required by a given treatment to adequately lower CPA and thus reduce pulsatile and net right ventricular afterload. Current monotherapies for pulmonary hypertension are not reducing pulsatile afterload in most patients, identifying an area of clinical need. We also found that the RPA-CPA relationship is sensitive to changes in pulmonary venous pressure (mean pulmonary capillary wedge pressure) because elevation of this pressure lowers CPA for any given RPA, augmenting right ventricular pulsatile afterload. In patients with exertional dyspnea and a preserved ejection fraction who exhibit a marked rise in pulmonary capillary wedge pressure during exercise, we found a disproportionate decline in CPA and thus increased pulsatile load. This identifies a novel mechanism whereby left-side diastolic dysfunction contributes to right ventricular load. 
Conclusions
An Unsuspected Property of Natriuretic Peptides: Promotion of Calcium-Dependent Catecholamine Release Via Protein Kinase G-Mediated Phosphodiesterase Type 3 Inhibition
Summary-Natriuretic peptides have long been viewed as compensatory hormones that are upregulated in the setting of heart failure, affording beneficial cardiac and hemodynamic effects. Yet a recent large randomized trial with recombinant B-type natriuretic peptide (nesiritide) failed to reduce mortality or rehospitalization in heart failure patients. We tested whether unsuspected proadrenergic effects might oppose the anticipated benefits of natriuretic peptides. We report that brain natriuretic peptide increases norepinephrine release in the guinea pig heart ex vivo, an effect that is further enhanced in ischemia/reperfusion. In addition, natriuretic peptides elicit catecholamine exocytosis in sympathetic nerve terminals isolated from the guinea pig heart and in nerve growth factor-differentiated rat pheochromocytoma PC12 cells, a model of sympathetic nerve endings. This proexocytotic effect is likely due to a protein kinase G-mediated inhibition of phosphodiesterase type 3. This increases intraneuronal cAMP levels and protein kinase A activity, which culminates in increased intracellular calcium and norepinephrine release. Notably, these effects occur at concentrations of natriuretic peptides reached at cardiac sympathetic nerve endings in advanced congestive heart failure. We propose that this proadrenergic action may counteract any beneficial cardiac and hemodynamic effects of increasing natriuretic peptide levels in congestive heart failure and thus explain the ineffectiveness of nesiritide as a cardiac failure medication.
Conclusions-Our results show that natriuretic peptides, at concentrations likely to be reached at cardiac sympathetic nerve endings in advanced congestive heart failure, promote norepinephrine release via a protein kinase G-induced inhibition of phosphodiesterase type 3-mediated cAMP hydrolysis. We propose that this proadrenergic action may counteract the beneficial cardiac and hemodynamic effects of natriuretic peptides and thus explain the ineffectiveness of nesiritide as a cardiac failure medication. 39
Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials
Summary-Validation of biomarkers requires large cohorts reflecting a broad range of contemporary patients. In 5284 patients with chronic heart failure from 2 independent randomized clinical trials, the Valsartan Heart Failure Trial (Val-HeFT) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF), changes over time in circulating high-sensitivity cardiac troponin T were related to fatal and nonfatal outcomes. In both studies, increases in high-sensitivity cardiac troponin T levels over 3 to 4 months were associated with age, diabetes mellitus, and reduction in estimated glomerular filtration rate. Despite very low baseline levels, increases in high-sensitivity cardiac troponin T concentration were strongly associated with clinical outcome, even after adjustment for conventional risk factors and benchmark circulating biomarkers of cardiac function (N-terminal probrain natriuretic peptide) or inflammation (C-reactive protein). The discriminative value of changes in high-sensitivity cardiac troponin T was limited, however. The strength of these observations lies in the fact that the data were obtained in 2 independent samples that differed with respect to the origin of patients, length of follow-up, and prescription rate of comedications (with β-blockers and aldosterone receptor antagonists more frequent in GISSI-HF). These results are consistent with reports of worsening outcomes with increasing circulating troponin concentrations in community-dwelling older adults, in ambulatory patients with chronic heart failure, or in patients with chest pain. Although such changes may reflect normal biological variation, their relation with future adverse events regardless of baseline concentrations suggests that they may truly reflect dynamic changes in disease progression. Given the limited variability of troponin levels over time, the potential for using their changes to guide therapy of chronic heart failure is questionable.
Conclusions-Despite very low circulating concentrations, changes in hs-cTnT concentrations over time are robust predictors of future cardiovascular events in patients with chronic HF but add limited prognostic discrimination. 40
Glycogen Synthase Kinase-3α Limits Ischemic Injury, Cardiac Rupture, Post-Myocardial Infarction Remodeling and Death
Summary-Occlusion of a coronary artery typically leads to ST-segment elevation myocardial infarction, for which percutaneous coronary intervention (PCI) or, if PCI is not available, thrombolytics, are the standard of care. The pathways that determine the amount of injury following occlusion of a coronary artery are not clear. If the components of those pathways could be identified, novel therapeutics targeting them could be created. This might be of particular importance when PCI is not readily available or when there will be delays in accessing a catheterization laboratory. Herein, we identify a single factor, a protein kinase known as glycogen synthase kinase-3α (GSK-3α), that modulates injury post-coronary occlusion. In the absence of GSK-3α, infarct size is larger, and mortality, primarily because of cardiac rupture, is increased. Long-term, adverse remodeling including profound fibrosis, and contractile dysfunction leading to heart failure, are more pronounced. It is uncommon to see significant cardioprotection in the setting of a permanent coronary artery occlusion because of the complete absence of flow, but our studies suggest that strategies promoting activation of GSK-3α might prove beneficial, even in the setting of an occluded vessel.
Conclusions-GSK-3α confers resistance to ischemic injury, at least in part, via limiting apoptosis. Loss of GSK-3α promotes ischemic injury, increases risk of cardiac rupture, accentuates post-MI remodeling and left ventricular dysfunction, and increases the progression to heart failure. These findings are in striking contrast to multiple previous reports in which deletion or inhibition of GSK-3β is protective. 41
The Diagnostic Value of Physical Examination and Additional Testing in Primary Care Patients With Suspected Heart Failure
Summary-The initial diagnosis of new nonacute heart failure is as difficult as it is important, especially in settings where more advanced diagnostic tests, notably echocardiography, are not readily available. This diagnostic study demonstrates the importance of history taking and, in particular, physical examination in a large cohort of 721 patients suspected of having nonacute heart failure, 207 (28.7%) of whom were diagnosed with heart failure. When a primary care physician is confronted with a patient suspected of having nonacute heart failure, a diagnostic rule including age, objective evidence of prior coronary artery disease, use of a loop diuretic, displaced apex beat, basal or more pulmonary rales, irregularly irregular pulse, heart murmur suggestive of mitral regurgitation, pulse rate, and elevated jugular venous pressure, plus a single additional test, the NT-proBNP plasma level, can accurately predict the presence or absence of heart failure numerically. The rule had comparable performance in 2 validation datasets. Chest x-ray or ECG can be used in addition to or instead of the NT-proBNP measurement depending on local availability and other patient characteristics. It remains important for diagnosticians to maintain basic physical examination skill.
Conclusions-In this study, we estimated the quantitative diagnostic contribution of elements of the history and physical examination in the diagnosis of heart failure in primary care outpatients, which may help to improve clinical decision making. The largest additional quantitative diagnostic contribution to those elements was provided by measurement of NT-proBNP. For daily practice, a diagnostic rule was derived that may be useful to quantify the probability of heart failure in patients with new symptoms suggestive of heart failure. 42
Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo
Summary-Reduced left ventricular diastolic compliance contributes to the pathophysiology of heart failure with preserved ejection fraction, a disease entity with no effective therapy. In vitro studies suggest that cGMP may have favorable effects on diastolic function, in part via activation of cGMP-dependent protein kinase and titin phosphorylation. Phosphodiesterase-5A degrades cGMP, whereas nitric oxide and natriuretic peptides enhance cGMP production. We studied the effects of short-term treatment with sildenafil (a phosphodiesterase-5A inhibitor) and brain natriuretic peptide on diastolic function in vivo (pressure-volume analysis) and on skinned cardiomyocyte passive stiffness and myofilament protein phosphorylation (serial myocardial biopsies) in a canine model of heart failure with preserved ejection fraction (elderly dogs with experimental hypertension) and young normal controls. In vivo, plasma cGMP levels and left ventricular diastolic and systolic capacitance increased and ex vivo measurements of cardiomyocyte passive stiffness decreased during serial treatment with sildenafil and with brain natriuretic peptide. These functional changes were associated with increases in titin phosphorylation without effects on troponin I, troponin T, phospholamban, myosin light chain, or myosin binding protein C phosphorylation. These data suggest that therapies elevating cGMP may provide benefit in the treatment of heart failure with preserved ejection fraction and support further investigation of short-or long-term administration of cGMP-enhancing therapies in this syndrome.
